Summary
Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat B-cell lymphoma.[3][6]
| Gene therapy | |
|---|---|
| Target gene | CD19 |
| Clinical data | |
| Trade names | Breyanzi |
| Other names | JCAR017, LM |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a621017 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system.[6] The most common side effects include decreases in neutrophils (a type of white blood cell that fights infections), in red blood cells or in blood platelets (components that help the blood to clot), as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and tiredness.[4]
Lisocabtagene maraleucel, a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, is the third gene therapy approved by the US Food and Drug Administration (FDA) for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL).[6] Lisocabtagene maraleucel was approved for medical use in the United States in February 2021.[3][6]
Medical uses edit
In the US, lisocabtagene maraleucel is indicated for the treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or relapsed or refractory disease after two or more lines of systemic therapy.[2][3][7] It is also indicated for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.[3]
In the EU, lisocabtagene maraleucel is indicated for the treatment of adults with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.[4]
Lisocabtagene maraleucel is not indicated for the treatment of people with primary central nervous system lymphoma.[3][6]
Adverse effects edit
The FDA label carries a boxed warning for cytokine release syndrome (CRS), which is a systemic response to the activation and proliferation of CAR-T cells, causing high fever and flu-like symptoms and neurologic toxicities.[6]
In April 2024, the FDA label boxed warning was expanded to include T cell malignancies.[8]
History edit
Lisocabtagene maraleucel's safety and efficacy were established in a multicenter clinical trial of more than 250 adults with refractory or relapsed large B-cell lymphoma.[6] The complete remission rate after treatment was 54%.[6]
The FDA granted lisocabtagene maraleucel priority review, orphan drug, regenerative medicine advanced therapy (RMAT), and breakthrough therapy designations.[6][9] Lisocabtagene maraleucel is the first regenerative medicine therapy with RMAT designation to be licensed by the FDA.[6] The FDA granted approval of Breyanzi to Juno Therapeutics Inc., a Bristol-Myers Squibb Company.[6]
Efficacy was evaluated in TRANSFORM (NCT03575351), a randomized, open-label, multicenter trial in adults with primary refractory LBCL or relapse within twelve months of achieving complete response (CR) to first-line therapy.[9] Participants had not yet received treatment for relapsed or refractory lymphoma and were potential candidates for autologous HSCT.[9] A total of 184 participants were randomized 1:1 to receive a single infusion of lisocabtagene maraleucel following fludarabine and cyclophosphamide lymphodepleting chemotherapy or to receive second-line standard therapy, consisting of three cycles of chemoimmunotherapy followed by high-dose therapy and autologous HSCT in participants who attained CR or partial response (PR).[9]
Efficacy was also evaluated in PILOT (NCT03483103), a single-arm, open-label, multicenter trial in transplant-ineligible patients with relapsed or refractory LBCL after one line of chemoimmunotherapy.[9] The study enrolled participants who were ineligible for high-dose therapy and HSCT due to organ function or age, but who had adequate organ function for CAR-T cell therapy.[9] Efficacy was based on CR rate and duration of response (DOR) as determined by an IRC.[9] Of 74 participants who underwent leukapheresis (median age, 73 years), 61 (82%) received lisocabtagene maraleucel of whom 54% (95% CI: 41, 67) achieved CR.[9] The median DOR was not reached (95% CI: 11.2 months, not reached) in participants who achieved CR and 2.1 months (95% CI: 1.4, 2.3) in participants with a best response of PR.[9] Among all leukapheresed participants, the CR rate was 46% (95% CI: 34, 58).[9]
Society and culture edit
Legal status edit
In January 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Breyanzi, intended for the treatment of adults with relapsed or refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), after at least two previous lines of treatments.[10][11] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.[10] Lisocabtagene maraleucel was approved for medical use in the European Union in April 2022.[4][5]
Names edit
Lisocabtagene maraleucel is the international nonproprietary name (INN).[12]
References edit
- ^ "Summary Basis of Decision - Breyanzi". Health Canada. 16 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
- ^ a b "Breyanzi- lisocabtagene maraleucel kit". DailyMed. Archived from the original on 24 March 2024. Retrieved 24 March 2024.
- ^ a b c d e f "Breyanzi (lisocabtagene maraleucel)". U.S. Food and Drug Administration (FDA). 13 November 2020. Archived from the original on 24 March 2024. Retrieved 24 March 2024.
This article incorporates text from this source, which is in the public domain.
- ^ a b c d "Breyanzi EPAR". European Medicines Agency. 24 January 2022. Archived from the original on 24 March 2024. Retrieved 24 March 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Breyanzi Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
- ^ a b c d e f g h i j k "FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 5 February 2021. Archived from the original on 5 March 2022. Retrieved 5 February 2021. This article incorporates text from this source, which is in the public domain.
- ^ "FDA Roundup: March 15, 2024". U.S. Food and Drug Administration (FDA). 15 March 2024. Archived from the original on 16 March 2024. Retrieved 24 March 2024. This article incorporates text from this source, which is in the public domain.
- ^ "FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies". U.S. Food and Drug Administration (FDA). 18 April 2024. Archived from the original on 19 April 2024. Retrieved 19 April 2024. This article incorporates text from this source, which is in the public domain.
- ^ a b c d e f g h i j "FDA approves lisocabtagene maraleucel". U.S. Food and Drug Administration. 27 June 2022. Archived from the original on 28 June 2022. Retrieved 28 June 2022. This article incorporates text from this source, which is in the public domain.
- ^ a b "Breyanzi: Pending EC decision". European Medicines Agency (EMA). 28 January 2022. Archived from the original on 28 January 2022. Retrieved 28 January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma" (Press release). European Medicines Agency (EMA). 27 January 2022. Archived from the original on 28 January 2022. Retrieved 28 January 2022.
- ^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1): 82-3. hdl:10665/330896.
External links edit
- "Lisocabtagene maraleucel". NCI Drug Dictionary. National Cancer Institute.
- Clinical trial number NCT02631044 for "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)" at ClinicalTrials.gov
- Clinical trial number NCT03575351 for "A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)" at ClinicalTrials.gov
- Clinical trial number NCT03483103 for "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)" at ClinicalTrials.gov
